Sensus Healthcare (SRTS) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Oct. 31, 2021
Document Information Line Items
Entity Registrant Name	Sensus Healthcare, Inc.
Trading Symbol	SRTS
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		16,617,274
Amendment Flag	false
Entity Central Index Key	0001494891
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	true
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-37714
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1647271
Entity Address, Address Line One	851 Broken Sound Pkwy
Entity Address, Address Line Two	NW #215
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	(561)
Local Phone Number	922-5808
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 16,391	$ 14,907
Accounts receivable, net	4,069	3,776
Inventories	2,041	4,427
Prepaid and other current assets	1,968	2,061
Total current assets	24,469	25,171
Property and equipment, net	684	1,356
Intangibles, net	170	338
Deposits	69	69
Operating lease right-of-use assets, net	234	1,076
Total assets	25,626	28,010
Current liabilities
Accounts payable and accrued expenses	2,686	2,874
Deferred revenue, current portion	1,418	1,492
Operating lease liabilities, current portion	240	303
Loan payable	105
Product warranties	324	187
Total current liabilities	4,773	4,856
Loan payable		267
Operating lease liabilities		812
Deferred revenue, net of current portion	246	579
Total liabilities	5,019	6,514
Commitments and contingencies
Stockholders’ equity
Preferred stock, 5,000,000 shares authorized and none issued and outstanding
Common stock, $0.01 par value – 50,000,000 authorized; 16,694,311 issued and 16,617,274 outstanding at September 30, 2021; 16,564,311 issued and 16,491,103 outstanding at December 31, 2020	167	166
Additional paid-in capital	44,025	43,701
Treasury stock, 77,037 and 73,208 shares at cost, at September 30, 2021 and December 31, 2020, respectively	(325)	(310)
Accumulated deficit	(23,260)	(22,061)
Total stockholders’ equity	20,607	21,496
Total liabilities and stockholders’ equity	$ 25,626	$ 28,010

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,694,311	16,564,311
Common stock, shares outstanding	16,617,274	16,491,103
Treasury stock, shares	77,037	73,208

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Revenues	$ 5,525	$ 1,620	$ 14,017	$ 4,483
Cost of sales	2,324	948	5,885	2,462
Gross profit	3,201	672	8,132	2,021
Operating expenses
Selling and marketing	1,180	1,034	3,502	3,987
General and administrative	1,082	976	3,499	3,210
Research and development	744	941	2,330	3,315
Total operating expenses	3,006	2,951	9,331	10,512
Income (loss) from operations	195	(2,279)	(1,199)	(8,491)
Other income (expense):
Gain on acquisition		588		588
Interest income		2	1	66
Interest expense		(3)	(1)	(17)
Other income (expense), net		587		637
Net income (loss)	$ 195	$ (1,692)	$ (1,199)	$ (7,854)
Net income (loss) per share – basic (in Dollars per share)	$ 0.01	$ (0.1)	$ (0.07)	$ (0.48)
Net income (loss) per share – diluted (in Dollars per share)	$ 0.01	$ (0.1)	$ (0.07)	$ (0.48)
Weighted average number of shares used in computing net income (loss) per share – basic (in Shares)	16,486,969	16,453,603	16,470,258	16,427,524
Weighted average number of shares used in computing net income (loss) per share – diluted (in Shares)	16,498,832	16,453,603	16,470,258	16,427,524

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 165	$ 43,315	$ (253)	$ (15,226)	$ 28,001
Balance (in Shares) at Dec. 31, 2019	16,540,478		(54,698)
Stock-based compensation		155			155
Stock-based compensation (in Shares)	30,000
Surrender of shares for tax withholding on stock compensation			$ (3)		(3)
Surrender of shares for tax withholding on stock compensation (in Shares)			(742)
Net loss (income)				(3,587)	(3,587)
Balance at Mar. 31, 2020	$ 165	43,470	$ (256)	(18,813)	24,566
Balance (in Shares) at Mar. 31, 2020	16,570,478		(55,440)
Stock-based compensation		130			130
Stock-based compensation (in Shares)	5,000
Surrender of shares for tax withholding on stock compensation			$ (54)		(54)
Surrender of shares for tax withholding on stock compensation (in Shares)			(17,768)
Exercise of warrants		1			1
Exercise of warrants (in Shares)	83
Net loss (income)				(2,574)	(2,574)
Balance at Jun. 30, 2020	$ 165	43,601	$ (310)	(21,387)	22,069
Balance (in Shares) at Jun. 30, 2020	16,575,561		(73,208)
Stock-based compensation		37			37
Net loss (income)				(1,692)	(1,692)
Balance at Sep. 30, 2020	$ 165	43,638	$ (310)	(23,079)	20,414
Balance (in Shares) at Sep. 30, 2020	16,575,561		(73,208)
Balance at Dec. 31, 2020	$ 166	43,701	$ (310)	(22,061)	21,496
Balance (in Shares) at Dec. 31, 2020	16,564,311		(73,208)
Stock-based compensation		60			60
Surrender of shares for tax withholding on stock compensation			$ (6)		(6)
Surrender of shares for tax withholding on stock compensation (in Shares)			(1,484)
Net loss (income)				(1,115)	(1,115)
Balance at Mar. 31, 2021	$ 166	43,761	$ (316)	(23,176)	20,435
Balance (in Shares) at Mar. 31, 2021	16,564,311		(74,692)
Stock-based compensation		59			59
Net loss (income)				(279)	(279)
Balance at Jun. 30, 2021	$ 166	43,820	$ (316)	(23,455)	20,215
Balance (in Shares) at Jun. 30, 2021	16,564,311		(74,692)
Stock-based compensation	$ 1	205			206
Stock-based compensation (in Shares)	130,000
Surrender of shares for tax withholding on stock compensation			$ (9)		(9)
Surrender of shares for tax withholding on stock compensation (in Shares)			(2,345)
Net loss (income)				195	195
Balance at Sep. 30, 2021	$ 167	$ 44,025	$ (325)	$ (23,260)	$ 20,607
Balance (in Shares) at Sep. 30, 2021	16,694,311		(77,037)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (1,199)	$ (7,854)
Adjustments to reconcile net loss to net cash and cash equivalents provided by (used in) operating activities:
Bad debts (recovery)		24
Depreciation and amortization	472	484
Loss on sale of property and equipment	46
Gain resulting from termination of lease	(38)
Provision for product warranties	262	167
Stock-based compensation	325	324
Impairment of intangible assets	88
Gain on bargain purchase		(588)
Changes in operating assets decrease (increase):
Accounts receivable	(293)	12,688
Inventories	2,453	(2,288)
Prepaid and other current assets	254	(137)
Changes in operating liabilities increase (decrease):
Accounts payable and accrued expenses	(343)	(2,515)
Deferred revenue	(408)	(120)
Product warranties	(125)	(259)
Total adjustments	2,693	7,780
Net cash provided by (used in) operating activities	1,494	(74)
Cash flows from investing activities
Acquisition of property and equipment	(90)	(255)
Proceeds from the sale of property and equipment	257
Investments matured		7,389
Net cash provided by investing activities	167	7,134
Cash flows from financing activities
Loan proceeds		1,023
Principal repayment of loan payable	(162)
Withholding taxes on stock-based compensation	(15)	(57)
Exercise of warrants		1
Net cash provided by (used in) financing activities	(177)	967
Net increase in cash and cash equivalents	1,484	8,027
Cash and cash equivalents – beginning of period	14,907	8,100
Cash and cash equivalents – end of period	16,391	16,127
Supplemental disclosure of cash flow information:
Interest paid	1	12
Supplemental schedule of noncash investing and financing transactions:
Transfer of inventory to property and equipment	66
Decrease in operating lease right-of-use assets and operating lease liabilities resulting from early termination of lease	$ (655)

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 1 — Organization and Summary of Significant Accounting Policies Description of the Business Sensus Healthcare, Inc. (together, with its subsidiary, unless the context otherwise indicates, “Sensus” or the “Company”) is a manufacturer of radiation therapy devices and sells the devices to healthcare providers globally through its distribution and marketing network. The Company operates in one segment from its corporate headquarters located in Boca Raton, Florida. Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its subsidiary. Accounts and transactions between consolidated entities have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Certain financial information that normally is included in annual financial statements, including certain financial statement footnotes, is not required for interim reporting purposes and has been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (“SEC”) on March 5, 2021 (the “2020 Annual Report”). The interim financial information at September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 is unaudited. However, in the opinion of management, the interim information includes all normal recurring adjustments necessary for the fair presentation of the Company’s results for the periods presented. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year. Revenue Recognition Revenue is recognized upon the transfer of control of promised goods or services to customers for an amount to which the Company expects to be entitled in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct. The Company’s revenue consists of sales of the Company’s devices and services related to maintaining and repairing the devices. The agreement for the sale of the devices and the service contract are usually signed at the same time, and in some instances a service contract is signed on a stand-alone basis. Revenue for service contracts is recognized over the service contract period on a straight-line basis. The Company has determined that in practice no significant discount is given on the service contract when it is offered with the device purchase as compared to when it is sold on a stand-alone basis. The service level provided is identical when the service contract is on a purchased stand-alone basis or together with the device. There is no termination provision in the service contract nor any penalties in practice for cancellation of the service contract. Disaggregated revenue for the three and nine months ended September 30, 2021 and 2020 was as follows: For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 Product Revenue $ 4,392 $ 475 $ 10,316 $ 1,621 Service Revenue 1,133 1,145 3,701 2,862 Total Revenue $ 5,525 $ 1,620 $ 14,017 $ 4,483 The Company operates in a highly regulated environment, primarily in the U.S. dermatology market, in which state regulatory approval is sometimes required prior to the customer being able to use the product. In cases where such regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained. Deferred revenue as of September 30, 2021 was as follows: (in thousands) Product Service Total Balance, beginning of period $ 23 $ 2,048 $ 2,071 Revenue recognized (30 ) (2,367 ) (2,397 ) Amounts refunded (3 ) - (3 ) Amounts invoiced 110 1,883 1,993 Balance, end of period $ 100 $ 1,564 $ 1,664 The Company does not disclose information about remaining performance obligations with original expected durations of one year or less in connection with deposits for products. Estimated service revenue to be recognized in the future related to the performance obligations that are fully or partially unsatisfied as of September 30, 2021 is as follows: (in thousands) Year Service Revenue 2021 (October 1 – December 31, 2021) $ 514 2022 868 2023 118 2024 61 2025 3 Total $ 1,564 The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product subject to the terms of the relevant warranty. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management’s estimate of the future claims rate. Shipping and handling costs are expensed as incurred and are included in cost of sales. Segment and Geographical Information The following table illustrates total revenue for the three and nine months ended September 30, 2021 and 2020 by geographic region. For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 United States $ 5,344 97 % $ 1,280 79 % $ 13,062 93 % $ 4,128 92 % China 170 3 % 334 21 % 939 7 % 334 8 % Israel 11 0 % 6 0 % 16 0 % 21 0 % Total Revenue $ 5,525 100 % $ 1,620 100 % 14,017 100 % $ 4,483 100 % One customer in the U.S. accounted for approximately 43% and 32% of revenues for the three months ended September 30, 2021 and 2020, respectively; approximately 35% and 23% for the nine months ended September 30, 2021 and 2020, respectively; and approximately 58% and 56% of the accounts receivable as of September 30, 2021 and December 31, 2020, respectively. Fair Value of Financial Instruments Carrying amounts of cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short maturities. Fair Value Measurements The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: Level 1 Inputs: Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date. ● Level 1 assets may include listed mutual funds, ETFs and listed equities Level 2 Inputs: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities that are not active; quotes from pricing services or brokers for which the Company can determine that orderly transactions took place at the quoted price or that the inputs used to arrive at the price are observable; and inputs other than quoted prices that are observable, such as models or other valuation methodologies. ● Level 2 assets may include debt securities and foreign currency exchange contracts that have inputs to the valuations that generally can be corroborated by observable market data. Level 3 Inputs: Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes. Level 3 assets include investments for which there is little, if any, market activity. These inputs require significant management judgment or estimation. Significance of Inputs: The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument. Cash and Cash Equivalents Cash and cash equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less. For purposes of the statements of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be cash equivalents. Accounts Receivable The Company does business and extends credit based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer, primarily due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for doubtful accounts was approximately $24 thousand as of September 30, 2021 and December 31, 2020. Inventories Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method. Earnings Per Share Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period, using the treasury stock method for options and warrants, as well as unvested restricted shares. In periods when the Company has incurred a net loss, options, warrants and unvested shares are considered common share equivalents but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive. Shares excluded were as follows: For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Shares — — 7,287 — Leases The Company evaluates arrangements at inception to determine if an arrangement is or contains a lease. Operating lease assets represent the Company’s right to use an underlying asset for the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the options. To determine the present value of the lease payment the Company uses an incremental borrowing rate that the Company would expect to incur for a fully collateralized loan over a similar term under similar economic conditions. The lease payments used to determine the Company’s operating lease assets may include lease incentives and stated rent increases and are recognized in the Company’s operating lease assets in the Company’s condensed consolidated balance sheets. Operating lease assets are amortized to rent expense over the lease term and included in operating expenses in the condensed consolidated statements of operations.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Business Combinations [Abstract]
ACQUISITIONS	Note 2 — Acquisitions On August 3, 2020, the Company acquired two mobile aesthetic laser companies, now known as Sensus Laser Aesthetic Solutions (“SLAS”), to complement and expand the Company’s offerings. The aggregate purchase price of $999 thousand was to be treated as compensation for post-acquisition services and to be recorded as compensation expense over the remaining service periods. During the three months ended June 30, 2021, the aggregate purchase price was reduced to $229 thousand due to the termination of the compensation arrangement with one of the parties. No further obligations are due to this party. In April 2021, the Company sold certain property and equipment acquired in one of the acquisitions for approximately $257 thousand to the terminated party. During the nine months ended September 30, 2021, the Company recorded $88 thousand of impairment charges on intangible assets and $46 thousand for a loss on the sale of property and equipment associated with this transaction. The Company does not expect to incur any additional impairment charges related to the acquisitions.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 3 — Property and Equipment (in thousands) As of As of Estimated (unaudited) Operations equipment $ 1,753 $ 2,178 3 years Tradeshow and demo equipment 925 923 3 years Computer equipment 124 119 3 years 2,802 3,220 Less accumulated depreciation (2,118 ) (1,864 ) Property and Equipment, Net $ 684 $ 1,356 Depreciation expense was approximately $103 thousand and $155 thousand, for the three months ended September 30, 2021 and 2020, respectively, and approximately $392 thousand and $407 thousand, for the nine months ended September 30, 2021 and 2020, respectively.

Intangibles

Intangibles	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES	Note 4 — Intangibles (in thousands) Patent Customer Trade Total December 31, 2020 $ 241 $ 84 $ 13 $ 338 Impairment charges - (81 ) (7 ) (88 ) Amortization expense (72 ) (2 ) (6 ) (80 ) September 30, 2021 $ 169 1 - 170

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
DEBT	Note 5 — Debt The Company has a revolving credit facility that, through March 2022, provides for maximum borrowings equal to the lesser of (a) the $10 million commitment amount or (b) the borrowing base plus a $3 million non-formula sublimit. The Company was in compliance with its financial covenants as of September 30, 2021 and December 31, 2020. There were no borrowings outstanding under the revolving credit facility at September 30, 2021 and December 31, 2020. The outstanding balance at September 30, 2021 and December 31, 2020 of the Small Business Administration loan to the Company under the Paycheck Protection Program enabled by the CARES Act of 2020 are reflected in Loan Payable in the condensed consolidated balance sheets.

Product Warranties

Product Warranties	9 Months Ended
	Sep. 30, 2021
Product Warranties Disclosures [Abstract]
PRODUCT WARRANTIES	Note 6 — Product Warranties Changes in product warranty liability were as follows for the nine months ended September 30, 2021: (in thousands) Balance, December 31, 2020 $ 187 Warranties accrued during the period 262 Payments on warranty claims (125 ) Balance, September 30, 2021 $ 324

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
LEASES	Note 7 — Leases Operating Lease Agreements The Company leases its headquarters office from an unrelated third party. The lease was last renewed in 2016 and expires in September 2022 with an option to extend with prior notice upon terms to be negotiated. The Company’s subsidiary leases a manufacturing facility with a 10-year lease expiring in July 2029. After 2, 4, 6 and 8 years, and with 180 days’ prior notice, the Company has the right to terminate the lease at its sole discretion without penalty. The Company has given such notice to terminate the lease and received confirmation from the landlord that the lease was terminated as of October 31, 2021. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2021. (in thousands) Maturity of Operating Lease Liabilities Amount 2021 (October 1 – December 31, 2021) $ 72 2022 183 Total undiscounted operating leases payments $ 255 Less: Imputed interest (15 ) Present Value of Operating Lease Liabilities $ 240 Other Information Weighted-average remaining lease term 0.9 years Weighted-average discount rate 5.0 % The right of use asset was reduced by approximately $842 thousand, including approximately $617 thousand related to the early termination of our subsidiary’s manufacturing facility lease, and $324 thousand for the nine months ended September 30, 2021 and the year ended December 31, 2020, respectively. Cash paid for amounts included in the present value of operating lease liabilities was approximately $259 thousand and $359 thousand for the nine months ended September 30, 2021 and the year ended December 31, 2020, respectively, and is included in cash flows from operating activities in the accompanying consolidated statement of cash flows. Operating lease cost was approximately $264 thousand and $285 thousand for the nine months ended September 30, 2021 and 2020, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 8 — Commitments and Contingencies Manufacturing Agreement In 2010, the Company entered into a three-year contract manufacturing agreement with an unrelated third party for the production and manufacture of the SRT-100 (and subsequently the SRT-100 Vision and the SRT-100 Plus), in accordance with the Company’s product specifications. The agreement renews for successive one-year periods unless either party notifies the other party in writing, at least 60 days prior to the anniversary date of the agreement, that it will not renew the agreement. The Company or the manufacturer may also terminate the agreement upon 90 days’ prior written notice. Purchases from this manufacturer totaled approximately $3.4 million and $551 thousand for the three months ended September 30, 2021 and 2020, respectively and approximately $3.8 million and $2.4 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, and December 31, 2020 approximately $720 thousand and $697 thousand, respectively, was due to this manufacturer, which is presented in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets. Legal contingencies The Company is party to certain legal proceedings in the ordinary course of business. The Company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and related contingencies. In 2015, the Company learned that the Department of Justice (the “Department”) had commenced an investigation of the billing to Medicare by a physician who had treated patients with the Company’s SRT-100. The Department subsequently advised the Company that it was considering expanding the investigation to determine whether the Company had any involvements in physician’s use of certain reimbursements codes. The Company has received two Civil Investigative Demands from the Department seeking documents and written responses in connection with its investigation. The Company has fully cooperated with the Department. The Company disputes that it has engaged in any wrongdoing with respect to such reimbursement claims; among other things, the Company does not submit claims for reimbursement or provide coding or billing advice to physicians. To the Company’s knowledge, the Department has made no determination as to whether the Company engaged in any wrongdoing, or whether to pursue any legal action against the Company. Should the Department decide to pursue legal action, the Company believes it has strong and meritorious defenses and will vigorously defend itself. At this time, the Company is unable to estimate the cost associated with this matter.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	Note 9 — STOCK-BASED COMPENSATION Warrants The following table summarizes the Company’s warrant activity: Warrants Number of Weighted Weighted Outstanding – December 31, 2020 138,000 $ 6.75 0.44 Granted — — — Exercised — — — Expired (138,000 ) 6.75 — Outstanding and exercisable – September 30, 2021 — $ — — The intrinsic value of the common stock warrants was approximately $0 as of September 30, 2021, and December 31, 2020, respectively. 2016 and 2017 Equity Incentive Plans Awards for up to 397,473 shares of common stock may be granted under the Company’s 2016 Equity Incentive Plan, and for up to 500,000 shares may be granted under its 2017 Equity Incentive Plan. The awards may be made in the form of restricted stock awards and stock options, among other things. In addition, unless the Compensation Committee specifically determines otherwise, the maximum number of shares available under the 2016 and 2017 Plans and the awards granted under those plans will be subject to appropriate adjustment in the case of any stock dividends, stock splits, recapitalizations, reorganizations, mergers, consolidations, exchanges or other changes in capitalization affecting our common stock. On July 21, 2021, a total of 130,000 shares of restricted stock were issued to employees and board members and were recorded at the fair value of $3.84 per share. The restricted shares vest 25% at grant date and 25% per year over a three-year Restricted stock activity for the nine months ended September 30, 2021 is summarized below: Outstanding at Restricted Stock Weighted- December 31, 2020 37,500 $ 4.17 Granted 130,000 3.84 Vested (43,750 ) 3.96 Forfeited - - September 30, 2021 123,750 $ 3.90 The Company recognizes forfeitures as they occur rather than estimating a forfeiture rate. The reduction of stock compensation expense related to the forfeitures was $0 for the nine months ended September 30, 2021 and 2020, respectively. Unrecognized stock compensation expense was approximately $494 thousand as of September 30, 2021, which will be recognized over a weighted-average period of 2.3 years. The stock compensation expense was approximately $204 thousand and $37 thousand, for the three months ended September 30, 2021 and 2020, respectively, and approximately $324 thousand, for the nine months ended September 30, 2021 and 2020. The following table summarizes the Company’s stock option activity: Outstanding at Number of Weighted- Weighted- December 31, 2020 229,334 $ 5.55 7.07 Granted — — — Exercised — — — Expired — — — September 30, 2021 229,334 $ 5.55 6.33 Exercisable – September 30, 2021 229,334 $ 5.55 6.33 The stock options had an intrinsic value of $0 as of September 30, 2021 and December 31, 2020, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	Note 10 — Income Taxes Book income before taxes was negative for the nine months ended September 30, 2021. Tax expense for the nine months ended September 30, 2021 and 2020 was $0. There are no uncertain tax positions that would require recognition in the consolidated financial statements. If the Company incurs an income tax liability in the future, interest on any income tax liability would be reported as interest expense, and penalties on any income tax liability would be reported as income taxes. The Company’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analyses of tax laws, regulations and interpretations as well as other factors. The Company accounts for income taxes in accordance with ASC 740, Income Taxes As of September 30, 2021, the Company has U.S. federal and certain state tax returns subject to examination, beginning with those filed for the year ended December 31, 2017.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 11 — Subsequent Events The Company has evaluated subsequent events and transactions that occur after the balance sheet date up to the date that the financial statements were issued for potential recognition or disclosure and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
DESCRIPTION OF THE BUSINESS	Description of the Business Sensus Healthcare, Inc. (together, with its subsidiary, unless the context otherwise indicates, “Sensus” or the “Company”) is a manufacturer of radiation therapy devices and sells the devices to healthcare providers globally through its distribution and marketing network. The Company operates in one segment from its corporate headquarters located in Boca Raton, Florida.
BASIS OF PRESENTATION	Basis of Presentation These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include the accounts of the Company and its subsidiary. Accounts and transactions between consolidated entities have been eliminated. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Certain financial information that normally is included in annual financial statements, including certain financial statement footnotes, is not required for interim reporting purposes and has been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes related thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (“SEC”) on March 5, 2021 (the “2020 Annual Report”). The interim financial information at September 30, 2021 and for the three and nine months ended September 30, 2021 and 2020 is unaudited. However, in the opinion of management, the interim information includes all normal recurring adjustments necessary for the fair presentation of the Company’s results for the periods presented. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year.
REVENUE RECOGNITION	Revenue Recognition Revenue is recognized upon the transfer of control of promised goods or services to customers for an amount to which the Company expects to be entitled in exchange for those goods or services. The Company enters into contracts that can include multiple services, which are accounted for separately if they are determined to be distinct. The Company’s revenue consists of sales of the Company’s devices and services related to maintaining and repairing the devices. The agreement for the sale of the devices and the service contract are usually signed at the same time, and in some instances a service contract is signed on a stand-alone basis. Revenue for service contracts is recognized over the service contract period on a straight-line basis. The Company has determined that in practice no significant discount is given on the service contract when it is offered with the device purchase as compared to when it is sold on a stand-alone basis. The service level provided is identical when the service contract is on a purchased stand-alone basis or together with the device. There is no termination provision in the service contract nor any penalties in practice for cancellation of the service contract. Disaggregated revenue for the three and nine months ended September 30, 2021 and 2020 was as follows: For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 Product Revenue $ 4,392 $ 475 $ 10,316 $ 1,621 Service Revenue 1,133 1,145 3,701 2,862 Total Revenue $ 5,525 $ 1,620 $ 14,017 $ 4,483 The Company operates in a highly regulated environment, primarily in the U.S. dermatology market, in which state regulatory approval is sometimes required prior to the customer being able to use the product. In cases where such regulatory approval is pending, revenue is deferred until such time as regulatory approval is obtained. Deferred revenue as of September 30, 2021 was as follows: (in thousands) Product Service Total Balance, beginning of period $ 23 $ 2,048 $ 2,071 Revenue recognized (30 ) (2,367 ) (2,397 ) Amounts refunded (3 ) - (3 ) Amounts invoiced 110 1,883 1,993 Balance, end of period $ 100 $ 1,564 $ 1,664 The Company does not disclose information about remaining performance obligations with original expected durations of one year or less in connection with deposits for products. Estimated service revenue to be recognized in the future related to the performance obligations that are fully or partially unsatisfied as of September 30, 2021 is as follows: (in thousands) Year Service Revenue 2021 (October 1 – December 31, 2021) $ 514 2022 868 2023 118 2024 61 2025 3 Total $ 1,564 The Company provides warranties, generally for one year, in conjunction with the sale of its products. These warranties entitle the customer to repair, replacement, or modification of the defective product subject to the terms of the relevant warranty. The Company records an estimate of future warranty claims at the time it recognizes revenue from the sale of the device based upon management’s estimate of the future claims rate. Shipping and handling costs are expensed as incurred and are included in cost of sales.
SEGMENT AND GEOGRAPHICAL INFORMATION	Segment and Geographical Information The following table illustrates total revenue for the three and nine months ended September 30, 2021 and 2020 by geographic region. For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 United States $ 5,344 97 % $ 1,280 79 % $ 13,062 93 % $ 4,128 92 % China 170 3 % 334 21 % 939 7 % 334 8 % Israel 11 0 % 6 0 % 16 0 % 21 0 % Total Revenue $ 5,525 100 % $ 1,620 100 % 14,017 100 % $ 4,483 100 % One customer in the U.S. accounted for approximately 43% and 32% of revenues for the three months ended September 30, 2021 and 2020, respectively; approximately 35% and 23% for the nine months ended September 30, 2021 and 2020, respectively; and approximately 58% and 56% of the accounts receivable as of September 30, 2021 and December 31, 2020, respectively.
FAIR VALUE OF FINANCIAL INSTRUMENTS	Fair Value of Financial Instruments Carrying amounts of cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short maturities.
FAIR VALUE MEASUREMENTS	Fair Value Measurements The Company uses a fair value hierarchy that prioritizes inputs to valuation approaches used to measure fair value. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories: Level 1 Inputs: Quoted prices (unadjusted) in active markets for identical assets or liabilities at the reporting date. ● Level 1 assets may include listed mutual funds, ETFs and listed equities Level 2 Inputs: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities that are not active; quotes from pricing services or brokers for which the Company can determine that orderly transactions took place at the quoted price or that the inputs used to arrive at the price are observable; and inputs other than quoted prices that are observable, such as models or other valuation methodologies. ● Level 2 assets may include debt securities and foreign currency exchange contracts that have inputs to the valuations that generally can be corroborated by observable market data. Level 3 Inputs: Unobservable inputs for the valuation of the asset or liability, which may include nonbinding broker quotes. Level 3 assets include investments for which there is little, if any, market activity. These inputs require significant management judgment or estimation. Significance of Inputs: The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the financial instrument.
CASH AND CASH EQUIVALENTS	Cash and Cash Equivalents Cash and cash equivalents primarily consist of cash, money market funds and short-term, highly liquid investments with original maturities of three months or less. For purposes of the statements of cash flows, the Company considers all highly liquid financial instruments with a maturity of three months or less when purchased to be cash equivalents.
ACCOUNTS RECEIVABLE	Accounts Receivable The Company does business and extends credit based on an evaluation of each customer’s financial condition, generally without requiring collateral. Exposure to losses on receivables is expected to vary by customer, primarily due to the financial condition of each customer. The Company monitors exposure to credit losses and maintains allowances for anticipated losses considered necessary under the circumstances. The allowance for doubtful accounts was approximately $24 thousand as of September 30, 2021 and December 31, 2020.
INVENTORIES	Inventories Inventories consist of finished product and components and are stated at the lower of cost or net realizable value, determined using the first-in-first-out method.
EARNINGS PER SHARE	Earnings Per Share Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding for the period. Diluted net income per share is computed by giving effect to all potential dilutive common share equivalents outstanding for the period, using the treasury stock method for options and warrants, as well as unvested restricted shares. In periods when the Company has incurred a net loss, options, warrants and unvested shares are considered common share equivalents but have been excluded from the calculation of diluted net loss per share as their effect is antidilutive. Shares excluded were as follows: For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Shares — — 7,287 —
LEASES	Leases The Company evaluates arrangements at inception to determine if an arrangement is or contains a lease. Operating lease assets represent the Company’s right to use an underlying asset for the lease term, and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the options. To determine the present value of the lease payment the Company uses an incremental borrowing rate that the Company would expect to incur for a fully collateralized loan over a similar term under similar economic conditions. The lease payments used to determine the Company’s operating lease assets may include lease incentives and stated rent increases and are recognized in the Company’s operating lease assets in the Company’s condensed consolidated balance sheets. Operating lease assets are amortized to rent expense over the lease term and included in operating expenses in the condensed consolidated statements of operations.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of disaggregation of revenue	For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 Product Revenue $ 4,392 $ 475 $ 10,316 $ 1,621 Service Revenue 1,133 1,145 3,701 2,862 Total Revenue $ 5,525 $ 1,620 $ 14,017 $ 4,483
Schedule of deferred revenue	(in thousands) Product Service Total Balance, beginning of period $ 23 $ 2,048 $ 2,071 Revenue recognized (30 ) (2,367 ) (2,397 ) Amounts refunded (3 ) - (3 ) Amounts invoiced 110 1,883 1,993 Balance, end of period $ 100 $ 1,564 $ 1,664
Schedule of estimated service revenue recognized	Year Service Revenue 2021 (October 1 – December 31, 2021) $ 514 2022 868 2023 118 2024 61 2025 3 Total $ 1,564
Schedule of table illustrates total revenue geographic region	For the Three Months Ended For the Nine Months Ended September 30, September 30, (in thousands) 2021 2020 2021 2020 United States $ 5,344 97 % $ 1,280 79 % $ 13,062 93 % $ 4,128 92 % China 170 3 % 334 21 % 939 7 % 334 8 % Israel 11 0 % 6 0 % 16 0 % 21 0 % Total Revenue $ 5,525 100 % $ 1,620 100 % 14,017 100 % $ 4,483 100 %
Schedule of basic net income (loss) per share	For the Three Months Ended For the Nine Months Ended 2021 2020 2021 2020 Shares — — 7,287 —

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	(in thousands) As of As of Estimated (unaudited) Operations equipment $ 1,753 $ 2,178 3 years Tradeshow and demo equipment 925 923 3 years Computer equipment 124 119 3 years 2,802 3,220 Less accumulated depreciation (2,118 ) (1,864 ) Property and Equipment, Net $ 684 $ 1,356

Intangibles (Tables)

Intangibles (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	(in thousands) Patent Customer Trade Total December 31, 2020 $ 241 $ 84 $ 13 $ 338 Impairment charges - (81 ) (7 ) (88 ) Amortization expense (72 ) (2 ) (6 ) (80 ) September 30, 2021 $ 169 1 - 170

Product Warranties (Tables)

Product Warranties (Tables)	9 Months Ended
	Sep. 30, 2021
Product Warranties Disclosures [Abstract]
Schedule of changes in product warranty liability	(in thousands) Balance, December 31, 2020 $ 187 Warranties accrued during the period 262 Payments on warranty claims (125 ) Balance, September 30, 2021 $ 324

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of future minimum lease payments for operating leases	Maturity of Operating Lease Liabilities Amount 2021 (October 1 – December 31, 2021) $ 72 2022 183 Total undiscounted operating leases payments $ 255 Less: Imputed interest (15 ) Present Value of Operating Lease Liabilities $ 240 Other Information Weighted-average remaining lease term 0.9 years Weighted-average discount rate 5.0 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of warrant activity	Warrants Number of Weighted Weighted Outstanding – December 31, 2020 138,000 $ 6.75 0.44 Granted — — — Exercised — — — Expired (138,000 ) 6.75 — Outstanding and exercisable – September 30, 2021 — $ — —
Schedule of restricted activity	Outstanding at Restricted Stock Weighted- December 31, 2020 37,500 $ 4.17 Granted 130,000 3.84 Vested (43,750 ) 3.96 Forfeited - - September 30, 2021 123,750 $ 3.90
Schedule of stock option activity	Outstanding at Number of Weighted- Weighted- December 31, 2020 229,334 $ 5.55 7.07 Granted — — — Exercised — — — Expired — — — September 30, 2021 229,334 $ 5.55 6.33 Exercisable – September 30, 2021 229,334 $ 5.55 6.33

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Organization and Summary of Significant Accounting Policies (Details) [Line Items]
Allowance for doubtful accounts receivable, current (in Dollars)	$ 24		$ 24		$ 24
U.S [Member] | Customer [Member]
Organization and Summary of Significant Accounting Policies (Details) [Line Items]
Revenue percentage	43.00%	32.00%	35.00%	23.00%
U.S [Member] | Customer [Member] | Accounts Receivable [Member]
Organization and Summary of Significant Accounting Policies (Details) [Line Items]
Revenue percentage			58.00%		56.00%

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenue - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Organization and Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenue [Line Items]
Total Revenue	$ 5,525	$ 1,620	$ 14,017	$ 4,483
Product Revenue [Member]
Organization and Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenue [Line Items]
Total Revenue	4,392	475	10,316	1,621
Service Revenue [Member]
Organization and Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenue [Line Items]
Total Revenue	$ 1,133	$ 1,145	$ 3,701	$ 2,862

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies (Details) - Schedule of deferred revenue $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Organization and Summary of Significant Accounting Policies (Details) - Schedule of deferred revenue [Line Items]
Balance, beginning of period	$ 2,071
Revenue recognized	(2,397)
Amounts refunded	(3)
Amounts invoiced	1,993
Balance, end of period	1,664
Product [Member]
Organization and Summary of Significant Accounting Policies (Details) - Schedule of deferred revenue [Line Items]
Balance, beginning of period	23
Revenue recognized	(30)
Amounts refunded	(3)
Amounts invoiced	110
Balance, end of period	100
Service [Member]
Organization and Summary of Significant Accounting Policies (Details) - Schedule of deferred revenue [Line Items]
Balance, beginning of period	2,048
Revenue recognized	(2,367)
Amounts refunded
Amounts invoiced	1,883
Balance, end of period	$ 1,564

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies (Details) - Schedule of estimated service revenue recognized $ in Thousands	Sep. 30, 2021USD ($)
Schedule of estimated service revenue recognized [Abstract]
2021 (October 1 – December 31, 2021)	$ 514
2022	868
2023	118
2024	61
2025	3
Total	$ 1,564

Organization and Summary of S_7

Organization and Summary of Significant Accounting Policies (Details) - Schedule of table illustrates total revenue geographic region - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenue	$ 5,525	$ 1,620	$ 14,017	$ 4,483
Total revenue, percentage	100.00%	100.00%	100.00%	100.00%
United States [Member]
Segment Reporting Information [Line Items]
Total revenue	$ 5,344	$ 1,280	$ 13,062	$ 4,128
Total revenue, percentage	97.00%	79.00%	93.00%	92.00%
China [Member]
Segment Reporting Information [Line Items]
Total revenue	$ 170	$ 334	$ 939	$ 334
Total revenue, percentage	3.00%	21.00%	7.00%	8.00%
Israel [Member]
Segment Reporting Information [Line Items]
Total revenue	$ 11	$ 6	$ 16	$ 21
Total revenue, percentage	0.00%	0.00%	0.00%	0.00%

Organization and Summary of S_8

Organization and Summary of Significant Accounting Policies (Details) - Schedule of basic net income (loss) per share - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Schedule of basic net income (loss) per share [Abstract]
Shares			7,287

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	Aug. 03, 2020	Jun. 30, 2021	Sep. 30, 2021	Apr. 30, 2021
Acquisitions (Details) [Line Items]
Property and equipment acquired				$ 257
Intangible asset			$ 88
Loss on sale of property and equipment			$ (46)
Sensus Laser Aesthetic Solutions [Member]
Acquisitions (Details) [Line Items]
Purchase price	$ 999	$ 229

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 103	$ 155	$ 392	$ 407

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 2,802	$ 3,220
Less accumulated depreciation	(2,118)	(1,864)
Property and Equipment, Net	684	1,356
Operations equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 1,753	2,178
Property and Equipment, Estimated Useful Lives	3 years
Tradeshow and demo equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 925	923
Property and Equipment, Estimated Useful Lives	3 years
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 124	$ 119
Property and Equipment, Estimated Useful Lives	3 years

Intangibles (Details) - Schedul

Intangibles (Details) - Schedule of intangible assets $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Finite-Lived Intangible Assets [Line Items]
Beginning balance	$ 338
Impairment charges	(88)
Amortization expense	(80)
Ending balance	170
Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	241
Impairment charges
Amortization expense	(72)
Ending balance	169
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	84
Impairment charges	(81)
Amortization expense	(2)
Ending balance	1
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning balance	13
Impairment charges	(7)
Amortization expense	(6)
Ending balance

Debt (Details)

Debt (Details)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Revolving credit facility, description	The Company has a revolving credit facility that, through March 2022, provides for maximum borrowings equal to the lesser of (a) the $10 million commitment amount or (b) the borrowing base plus a $3 million non-formula sublimit.

Product Warranties (Details) -

Product Warranties (Details) - Schedule of changes in product warranty liability $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Schedule of changes in product warranty liability [Abstract]
Balance, beginning of period	$ 187
Warranties accrued during the period	262
Payments on warranty claims	(125)
Balance, end of period	$ 324

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Leases [Abstract]
Operating leases term, description	The Company’s subsidiary leases a manufacturing facility with a 10-year lease expiring in July 2029. After 2, 4, 6 and 8 years, and with 180 days’ prior notice, the Company has the right to terminate the lease at its sole discretion without penalty.
ROU assets was reduced	$ 842		$ 842
Termination of lease	617		617
Manufacturing facility lease	324		324
Cash paid for amounts included in present value of operating lease liabilities	259		$ 359
Operating lease cost	$ 264	$ 285

Leases (Details) - Schedule of

Leases (Details) - Schedule of future minimum lease payments for operating leases $ in Thousands	Sep. 30, 2021USD ($)
Schedule of future minimum lease payments for operating leases [Abstract]
2021 (October 1 – December 31, 2021)	$ 72
2022	183
Total undiscounted operating leases payments	255
Less: Imputed interest	(15)
Present Value of Operating Lease Liabilities	$ 240
Other Information
Weighted-average remaining lease term	10 months 24 days
Weighted-average discount rate	5.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Purchases from this manufacturer	$ 3,400	$ 551	$ 3,800	$ 2,400
Accounts payable and accrued expenses	$ 720		$ 720		$ 697

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 21, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Stock-Based Compensation (Details) [Line Items]
Intrinsic value of common stock warrants		$ 0		$ 0		$ 0
Restricted stock issued (in Shares)	130,000
Restricted stock fair value per share (in Dollars per share)	$ 3.84
Restricted shares vested	25.00%
Restricted shares grant date	25.00%
Vesting period	3 years
Reduction of stock compensation expense value forfeited				0	$ 0
Unrecognized stock compensation expense		494		$ 494
Weighted-average period				2 years 3 months 18 days
Stock compensation expense		204	$ 37	$ 324	$ 324
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 0		$ 0		$ 0
2016 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of authorized shares under the plan (in Shares)		397,473		397,473
2017 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Number of authorized shares under the plan (in Shares)		500,000		500,000

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of warrant activity	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Schedule of warrant activity [Abstract]
Number of Warrants , Outstanding at beginning	138,000
Weighted Average Exercise Price, Outstanding at beginning (in Dollars per share) | $ / shares	$ 6.75
Weighted Average Remaining Contractual Term (In Years), Outstanding at beginning	5 months 8 days
Number of Warrants, Granted
Weighted Average Exercise Price, Granted (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (In Years), Granted
Number of Warrants, Exercised
Weighted Average Exercise Price, Exercised (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (In Years), Exercised
Number of Warrants, Expired	(138,000)
Weighted Average Exercise Price, Expired (in Dollars per share) | $ / shares	$ 6.75
Weighted Average Remaining Contractual Term (In Years), Expired
Number of Warrants, Outstanding and exercisable at ending
Weighted Average Exercise Price, Outstanding and exercisable at ending (in Dollars per share) | $ / shares
Weighted Average Remaining Contractual Term (In Years), Outstanding and exercisable at ending

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of restricted activity	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Schedule of restricted activity [Abstract]
Restricted Stock, balance at beginning | shares	37,500
Weighted-Average Grant Date Fair Value, balance at beginning | $ / shares	$ 4.17
Restricted Stock, Granted | shares	130,000
Weighted-Average Grant Date Fair Value, Granted | $ / shares	$ 3.84
Restricted Stock, Vested | shares	(43,750)
Weighted-Average Grant Date Fair Value, Vested | $ / shares	$ 3.96
Restricted Stock, Forfeited | shares
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares
Restricted Stock, balance at ending | shares	123,750
Weighted-Average Grant Date Fair Value, balance at ending | $ / shares	$ 3.9

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of stock option activity	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Schedule of stock option activity [Abstract]
Number of Options, at beginning | shares	229,334
Weighted- Average Exercise Price, at beginning | $ / shares	$ 5.55
Weighted- Average Remaining Contractual Term (In Years), at beginning	7 years 25 days
Number of Options, Granted | shares
Weighted- Average Exercise Price, Granted | $ / shares
Weighted- Average Remaining Contractual Term (In Years), Granted
Number of Options, Exercised | shares
Weighted- Average Exercise Price, Exercised | $ / shares
Weighted- Average Remaining Contractual Term (In Years), Exercised
Number of Options, Expired | shares
Weighted- Average Exercise Price, Expired | $ / shares
Weighted- Average Remaining Contractual Term (In Years), Expired
Number of Options, Outstanding at end | shares	229,334
Weighted- Average Exercise Price, Outstanding at end | $ / shares	$ 5.55
Weighted- Average Remaining Contractual Term (In Years), Outstanding at ending	6 years 3 months 29 days
Number of Options, Exercisable | shares	229,334
Weighted- Average Exercise Price, Exercisable | $ / shares	$ 5.55
Weighted- Average Remaining Contractual Term (In Years), Exercisable	6 years 3 months 29 days

Income Taxes (Details)

Income Taxes (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Tax expense	$ 0	$ 0